Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT 2A) receptor and inverse agonist activity of naftidrofuryl: Comparison with those of sarpogrelate

Journal of Pharmacological Sciences

Volumn 110, Issue 4, 2009, Pages 445-450

  Aly, Saida Abdel Regal ^a   Hossain, Murad ^a   Bhuiyan, Mohiuddin Ahmed ^a   Nakamura, Takashi ^a   Nagatomo, Takafumi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Constitutively active mutant; Inverse agonist activity; Naftidrofuryl; Sarpogrelate

Indexed keywords

NAFTIDROFURYL; SARPOGRELATE; SEROTONIN 2A RECEPTOR;

ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MUTANT; WILD TYPE;

CELL LINE; DRUG INVERSE AGONISM; HUMANS; MUTATION; NAFRONYL; PROTEIN BINDING; PROTEIN TRANSPORT; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN ANTAGONISTS; SUCCINATES; VASODILATOR AGENTS;

EID: 68849098192     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09124FP     Document Type: Article

References (31)

1. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease ditection, awareness and treatment in primary care. JAMA. 2001;286:1317-1324. (Pubitemid 33015522)
2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33:S1-S75. (Pubitemid 46068992)
3. Dormandy JA, Eutherford RB. Management of peripheral arterial diease (PAD). TASC Working Group. Trans Atalntic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31:S1-S296.
4. Furukawa K, Tanabe T, Hoshino S, Mishima Y, Matsuo H, Ota T, et al. [Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive disease: a double-blind comparison with ticlopidine hydrochloride.] Jpn J Clin Pharmacol Ther. 1991;7:1747-1770. (in Japanese)
5. Hara H, Osakabe M, Kitajma A, Tamao Y, Kikumoto R. MCI-9042, a new antiplatelet agent is selective S2-serotonergic receptor antagonist. Thromb Haemost. 1991;65:415-420.
6. Sarma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS. Inhibition of serotonin-induced vasculalr smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther. 1999;290:1475-1481. (Pubitemid 29400293)
7. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological waliking distance in pathients with intermittent caludication. Ann Cardiol Angeiol (Paris). 2001;50:175-182. (Pubitemid 32318776)
8. Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol. 2001;20:58-65. (Pubitemid 32600428)
9. Spengel F, Clément D, Boccalon H, Liard F, Brown T, Lehert P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol. 2002;21:20-27. (Pubitemid 34413650)
10. 2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol. 2007;49:221-227.
11. Yamakawa J, Takahashi T, Saegusa S, Moriya J, Itoh T, Kusaka K, et al. Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. J Int Med Res. 2004; 32:166-169. (Pubitemid 38401083)
12. Egan CT, Herrick-Davis K, Teitler M. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of anti-psychotic drugs. J Pharmacol Exp Ther. 1998;286:85-90. (Pubitemid 28317977)
13. 2A receptor. J Pharmacol Sci. 2006;102:189-195.
14. 2A receptor determines relative efficacy. Mol Pharmacol. 2003;63:36-43.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
16. 2A receptor determines relative efficacy. Mol Pharmacol. 2003;63:36-43.
17. Furchgott RF. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E, editors. Handbook of experimental pharmacology, Vol.33, Catecholamines. Berlin: Springer; 1972. p. 283-335.
18. Endemann D, Schweda F, Stubanus M, Ittner KP, Fischereder M, Kammerl MC, et al. Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys. J Cardiovasc Pharmacol. 2002;39:1-8. (Pubitemid 34028547)
19. 2A antagonist Sarpogrelate on walking ability in patients with intermittent claudication as measured using the walking impairment questionnaire. Ann Vasc Dis. 2008;1;102-110.
20. 2C receptor subtypes by molecular modeling. Life Sci. 2003;73:193-207.
21. 2A serotonin receptor. J Pharmacol Sci. 2006;102:55-63.
22. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol. 1994;45:490-499. (Pubitemid 24094939)
23. Samama P, Pei G, Costa T, Cotecchia S, Lefkowitz RJ. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol Pharmacol. 1994;45:390-394. (Pubitemid 24094926)
24. Shryock JC, Ozeck MJ, Belardinelli L. Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol. 1998;53:886-893. (Pubitemid 28244076)
25. Spadoni G, Balsamini C, Bedini A, Diamantini G, DI Giacomo B, Tontini A, et al. 2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists and putative inverse agonists. J Med Chem. 1998;41:3624-3634.
26. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol. 2004;65:2-11. (Pubitemid 38113879)
27. Rossier O, Abuin L, Fanelli F, Leonardi A, Cotecchia S. Inverse agonism and neutral antagonism at α1a and α1b-adrenergic receptor subtypes. Mol Pharmacol. 1999;56:858-866.
28. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H1-receptor activation of nuclear factor-κB: roles of Gβγ- and Gαq/11-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol. 2001;60:1133-1142. (Pubitemid 33027449)
29. Behan DP, Chalmers DT. The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool. Curr Opin Drug Discov Devel. 2001;4:548-560.
30. Chalmers DT, Behan DP. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat Rev Drug Discov. 2002;1:599-608.
31. 2A receptor by site-directed mutagenesis: inverse agonist activity of anti-psychotic drugs. J Pharmacol Exp Ther. 1998;286:85-90.